Literature DB >> 21476914

Inflammation in nonalcoholic steatohepatitis.

R Christopher Harmon1, Dina G Tiniakos, Curtis K Argo.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) describes a range of disorders characterized by excess accumulation of triglyceride within the liver. While simple steatosis may be clinically stable, nonalcoholic steatohepatitis (NASH) can be progressive. Inflammation is believed to be the driving force behind NASH and the progression to fibrosis and subsequent cirrhosis. This article will review and interpret the current literature in an attempt to expand our understanding of the environmental and genetic causes of inflammation and its effects in NAFLD.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21476914     DOI： 10.1586/egh.11.21

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN： 1747-4124            Impact factor:   3.869


  32 in total

1.  HLA DQB1 alleles are related with nonalcoholic fatty liver disease.

Authors:  Levent Doganay; Seyma Katrinli; Yasar Colak; Ebubekir Senates; Ebru Zemheri; Oguzhan Ozturk; Feruze Yilmaz Enc; Ilyas Tuncer; Gizem Dinler Doganay
Journal:  Mol Biol Rep       Date:  2014-08-26       Impact factor: 2.316

2.  Metabolically induced liver inflammation leads to NASH and differs from LPS- or IL-1β-induced chronic inflammation.

Authors:  Wen Liang; Jan H Lindeman; Aswin L Menke; Debby P Koonen; Martine Morrison; Louis M Havekes; Anita M van den Hoek; Robert Kleemann
Journal:  Lab Invest       Date:  2014-02-24       Impact factor: 5.662

3.  Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway.

Authors:  Qiang Ou; Yuanyuan Weng; Siwei Wang; Yajuan Zhao; Feng Zhang; Jianhua Zhou; Xiaolin Wu
Journal:  Dig Dis Sci       Date:  2018-09-06       Impact factor: 3.199

Review 4.  Signal transductions and nonalcoholic fatty liver: a mini-review.

Authors:  Lu Zeng; Wai J Tang; Jin J Yin; Bei J Zhou
Journal:  Int J Clin Exp Med       Date:  2014-07-15

5.  Diethyldithiocarbamate, an anti-abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress.

Authors:  Tianhui Liu; Ping Wang; Min Cong; Xinyan Zhao; Dong Zhang; Hufeng Xu; Lin Liu; Jidong Jia; Hong You
Journal:  Br J Pharmacol       Date:  2018-10-23       Impact factor: 8.739

6.  Oligofructose protects against arsenic-induced liver injury in a model of environment/obesity interaction.

Authors:  Veronica L Massey; Kendall S Stocke; Robin H Schmidt; Min Tan; Nadim Ajami; Rachel E Neal; Joseph F Petrosino; Shirish Barve; Gavin E Arteel
Journal:  Toxicol Appl Pharmacol       Date:  2015-03-08       Impact factor: 4.219

7.  Probucol ameliorates the development of nonalcoholic steatohepatitis in rats fed high-fat diets.

Authors:  Rong Wu; Wei Zhang; Bo Liu; Jing Gao; Xiao-Qiu Xiao; Feng Zhang; Hua-Mei Zhou; Xiao-Ling Wu; Xia Zhang
Journal:  Dig Dis Sci       Date:  2012-08-10       Impact factor: 3.199

Review 8.  Pathogenesis of nonalcoholic steatohepatitis.

Authors:  Wensheng Liu; Robert D Baker; Tavleen Bhatia; Lixin Zhu; Susan S Baker
Journal:  Cell Mol Life Sci       Date:  2016-02-19       Impact factor: 9.261

9.  Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development.

Authors:  Yan Li; Jie Hai; Lake Li; Xuehui Chen; Hua Peng; Meng Cao; Qinggui Zhang
Journal:  Endocrine       Date:  2012-07-29       Impact factor: 3.633

10.  The administration of ghrelin improved hepatocellular injury following parenteral feeding in a rat model of short bowel syndrome.

Authors:  Shun Onishi; Tatsuru Kaji; Waka Yamada; Kazuhiko Nakame; Tomoe Moriguchi; Koushirou Sugita; Koji Yamada; Takafumi Kawano; Motoi Mukai; Masakazu Souda; Sohsuke Yamada; Takako Yoshioka; Akihide Tanimoto; Satoshi Ieiri
Journal:  Pediatr Surg Int       Date:  2016-09-20       Impact factor: 1.827
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.